Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies
Machine Learning Analysis of Expanded Two-photon Imaging of Skin Biopsy Specimens
The goal of this study is to investigate the ability of a machine learning model to evaluate two-photon fluorescence microscopy images of dermatologic biopsies at point of care.
The main question it aims to answer is:
• How well do two-photon fluorescence images of biopsies taken in a clinic and evaluated by a machine learning model agree with conventional histology?
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
This study will image biopsy specimens at point of care using two-photon fluorescence microscopy (TPFM) and then assess how well the images predict the eventual clinical diagnosis using a machine learning model. Because two-photon images can be acquired from small biopsy specimens within minutes of excision, they could potentially be used to immediately diagnose patients, but the accuracy of TPFM for various skin conditions is unknown.
Individual biopsy specimens in a dermatology clinic will be imaged using TPFM shortly after biopsy procedures. Immediately following imaging, a machine learning model will evaluate the TPFM images then compute a confidence score for a diagnosis of basal cell carcinoma (BCC), squamous cell carcinoma, and non-cancer. The relative confidence in each diagnosis will be compared, and if sufficient confidence is achieved, the model will render a diagnosis or else flag the specimen as indeterminate for manual pathologist review. This workflow will evaluate the use of ML + TPFM to perform point of care diagnosis of skin lesions.
Following TPFM imaging, the specimen will be submitted for histological processing, which will guide actual patient treatment. Following conclusion of patient treatment, the resulting histology slides will be scanned for comparison and the final patient diagnosis recorded. Images of the histology slides will be read by a pathologist to establish a gold-standard diagnosis. The official diagnosis and the diagnosis from the collaborating pathologist will be compared.
Patient treatment will still be decided by conventional histopathology. TPFM will not be used to change treatment.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Michael Giacomelli, Ph.D
- Número de teléfono: 5852766260
- Correo electrónico: mgiacome@ur.rochester.edu
Ubicaciones de estudio
-
-
New York
-
Victor, New York, Estados Unidos, 14654
- Reclutamiento
- Rochester Dermatologic Surgery
-
Contacto:
- Sherrif Ibrahim, M.D.-Ph.D.
- Número de teléfono: 585-222-1400
- Correo electrónico: dr.ibrahim@rochesterdermsurgery.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Punch, excisional or shave biopsy specimen
Exclusion Criteria:
- Biopsy indication includes melanoma or dysplastic/atypical nevus
- Excision thickness of less than 1 mm
- Excision longest dimension less than 2 mm
- Excision performed as multiple pieces in a single specimen container
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: TPFM imaging of biopsy
Specimens will be imaged with TPFM and diagnosed using a machine learning model
|
Ex vivo tissues will be imaged with two-photon microscopy and analyzed with machine learning for diagnosis
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Sensitivity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care
Periodo de tiempo: During or immediately following patient biopsy (same day)
|
A machine learning model will evaluate TPFM images of patient biopsies at point of care.
Sensitivity will be calculated for the machine learning model using two photon fluorescence microscopy images.
Sensitivity is defined as the number of true positive diagnoses divided by the sum of true positive and false negative diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis.
The patient's ultimate clinical diagnosis will serve as the reference standard.
|
During or immediately following patient biopsy (same day)
|
|
Specificity of Machine Learning Analysis of Two Photon Fluorescence Microscopy Images At Point of Care
Periodo de tiempo: During or immediately following patient biopsy (same day)
|
A machine learning model will evaluate TPFM images of patient biopsies at point of care.
Specificity will be calculated for the machine learning model using two photon fluorescence microscopy images.
Specificity is defined as the number of true negative diagnoses divided by the sum of true negative and false positive diagnoses among biopsy specimens for which the machine learning model provides a definitive diagnosis.
The patient's ultimate clinical diagnosis will serve as the reference standard.
|
During or immediately following patient biopsy (same day)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of Discordant Diagnoses Attributable to Machine Learning Model Interpretation Errors
Periodo de tiempo: After completion of patient diagnosis (typically 1-2 weeks after procedure)
|
For biopsy specimens with discordant diagnoses between the machine learning model and the patient's ultimate clinical diagnosis, a dermatopathologist will review each case and classify the source of disagreement as machine learning model interpretation error, image quality limitation, or image coregistration error.
The proportion of discordant diagnoses attributable to each source of disagreement will be reported.
|
After completion of patient diagnosis (typically 1-2 weeks after procedure)
|
|
Proportion of Biopsy Specimens With a Definitive Machine Learning Diagnosis
Periodo de tiempo: During or immediately following patient biopsy (same day)
|
The proportion of biopsy specimens for which the machine learning model provides a definitive diagnosis based on two photon fluorescence microscopy images will be calculated as the number of specimens receiving a definitive diagnosis divided by the total number of specimens evaluated.
|
During or immediately following patient biopsy (same day)
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY00009823B
- R37CA258376 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .